Top Story

PROTECT AF: LAA closure superior to warfarin in preventing outcomes at 3.8 years

November 24, 2014

New 3.8-year follow-up data from the PROTECT AF trial have shown that left atrial appendage closure met the criteria for superiority vs. warfarin for the prevention of a composite endpoint of adverse events in patients with nonvalvular atrial fibrillation at elevated risk for stroke.

These results come just more than a month after FDA advisory panel members were split on the revote for the left atrial appendage (LAA) occlusion device (Watchman, Boston Scientific), which was tested in the PROTECT AF and PREVAIL trials.

NAFLD associated with high BP, hypertension in children In the Journals

NAFLD associated with high BP, hypertension in children

November 24, 2014
Pediatric patients with nonalcoholic fatty liver disease were more likely to have high blood pressure and persistent high blood pressure compared with children without…
Meeting News Coverage

DEFEAT-HF: Spinal cord stimulation did not benefit patients with HF

November 24, 2014
CHICAGO — Implantation of a spinal cord stimulator was not associated with clinical benefit or improvement in outcomes as a treatment for advanced HF. Douglas P
Marc Pfeffer, MD Meeting News Coverage

TOPCAT: Spironolactone effectiveness differed by region

November 24, 2014
CHICAGO — The TOPCAT trial to show benefits for spironolactone in patients with HF with preserved ejection fraction was neutral overall, but the effectiveness of…
In the Journals

Rehospitalization common for survivors of in-hospital cardiac arrest

November 23, 2014
Patients who have survived an in-hospital cardiac arrest have high rates of hospital readmission, according to recent results.These readmission rates, along with…
More News Headlines »
CME
Risk Management in the Cardiovascular Disease Arena

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

This activity is supported by an educational grant from Genentech.

Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM)…
More »
Meeting News Coverage Video
Healio AHA2014 Zile th

New data may yield a 'change in the paradigm' of HF therapy

November 18, 2014
CHICAGO — Further analyses of the PARADIGM-HF trial provide more information on the efficacy of an…
More »
CME
Lipid Forum II Highlights

Lipid Forum II Highlights

This activity is supported by an educational grant from Genentech.

Risk stratification and appropriate therapies for various dyslipidemias remain difficult concepts for practitioners…
More »
morganatic-roan